COVID-19 Pandemic, Update # 45 SARS-CoV-2 Monoclonal Antibody Therapy Updates Resumption of Healthcare Provider & Public Health Partner Webinars

On September 17, 2021, NH DHHS issued a health alert on SARS-CoV-2 monoclonal antibody therapy updates.

NH DPHS Health AlertsKey Points and Recommendations:

  • Management of patients with COVID-19 vary by setting and severity of illness; providers should familiarize themselves with COVID-19 treatment guidelines from both the National Institutes of Health (NIH) and the Infectious Disease Society of America (IDSA) 
    • Note the NIH has updated their guidance on use of bamlanivimab plus etesevimab but this not yet been incorporated into their guidance summary 
    • Review the recent CDC HAN advising against the use of ivermectin, which has not been shown to be effective at treating or preventing COVID-19 
  • Three SARS-CoV-2 monoclonal antibody products are available for use under a U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA), including bamlanivimab plus etesevimab, casirivimab plus imdevimab, and sotrovimab 
    • Use these therapies for patients with mild to moderate confirmed COVID-19 infection and who are not hospitalized (unless hospitalized for a reason other than COVID-19) but are at high risk for progressing to severe disease and/or hospitalization 
    • Criteria for identifying patients that are at high risk for progressing to severe disease and/or hospitalization are listed on each product’s FDA Fact Sheet for Healthcare Providers (linked above). Note that use of these products under the EUA is not limited to only patients with the conditions listed, and providers may take patients’ unique risk profiles into account when deciding whether to use these therapies 
    • Casirivimab plus imdevimab has also received EUA as post-exposure prophylaxis (PEP) for patients who are at high risk of becoming infected and progressing to severe COVID-19; casirivimab plus imdevimab may also be given in subcutaneous injections if intravenous administration is not an option 
    • When supplies of monoclonal antibodies are limited, the NIH recommends that providers prioritize treatment over PEP 
  • Providers who want to refer an ambulatory patient for treatment with monoclonal antibodies should review the following map which identifies facilities that administer monoclonal antibodies, then contact that facility directly to refer a patient 
    • For patients in long-term care facilities (LTCF), the pharmacies that already support LTCFs are receiving monoclonal antibody treatments to use 
  • The U.S. Department of Health and Human Services (HHS) now distributes monoclonal antibody therapies through a state-coordinated allocation system; healthcare facilities can no longer order these products directly from the distributor (AmerisourceBergen) 
    • HHS will determine weekly distribution amounts for NH based on the weekly statewide incidence of new infections and hospitalizations, and product utilization 
    • The NH Division of Public Health Services (NH DPHS) will then allocate treatments to NH administration facilities based on their requests and utilization, and the products will ship directly to the facility from AmerisourceBergen 
    • For more information on this new process, see the HHS announcement 
    • To request supplies of monoclonal antibodies for administration, please e-mail, or call 603-271-4463 
  • NH DPHS will host webinars for School and Childcare Partners the 1st and 3rd Wednesday of each month from 3:30 – 4:30 pm (next meeting Wednesday 10/6): 
  • NH DPHS will resume webinars for Healthcare Providers and Public Health Partners the 2nd and 4th Thursday of each month from 12:00 – 1:00 pm (next meeting Thursday 9/23): 

Read the full DHHS Alert